公开(公告)号：US12128102B2

公开(公告)日：2024-10-29

申请号：US18357013

申请日：2023-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Patrick Baeuerle ,  Robert B. DuBridge ,  Holger Wesche ,  Luke Evnin ,  Jeanmarie Guenot ,  Anand Panchal ,  Maia Vinogradova

IPC: G01N31/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  G01N33/53 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/50

Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.